2015
Using hiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms
Flaherty E, Brennand K. Using hiPSCs to model neuropsychiatric copy number variations (CNVs) has potential to reveal underlying disease mechanisms. Brain Research 2015, 1655: 283-293. PMID: 26581337, PMCID: PMC4865445, DOI: 10.1016/j.brainres.2015.11.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCopy number variationsIsogenic hiPSC linesRare variantsFull genetic architectureGenome editing technologyPluripotent stem cellsStrong heritable componentPatient-derived humanGenetic architectureEditing technologyHeritable componentBehavioral defectsNumber variationsNew therapeutic targetsHiPSC linesGenetic backgroundStem cellsCommon variantsFunctional contributionDisease mechanismsSingle variantMouse modelHigh penetranceHiPSCsTherapeutic target
2014
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt E, Buchanan S, Brennand K, Merchant K. Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Frontiers In Pharmacology 2014, 5: 252. PMID: 25520658, PMCID: PMC4251289, DOI: 10.3389/fphar.2014.00252.Peer-Reviewed Original ResearchBiology approachNeurological disease pathwaysSpecific neural cell typesSystems biology approachPatient-derived hiPSCsDrug discoveryGeneration of hiPSCsInduced pluripotent stem cellsRepresentative neurological diseasesHuman induced pluripotent stem cellsNeural cell typesPluripotent stem cellsSingle geneGlobal epigeneticExpression studiesFrequent clinical failuresDrug screening strategiesNeurodegenerative diseases Alzheimer's diseaseHuman diseasesPsychiatric disorders schizophreniaCell typesCNS disordersHiPSC linesDisease pathwaysBiological networks